Literature DB >> 33941744

Evaluation of a Novel Culture System for Rapid Pathogen Identification and Detection of Cephalosporin Resistance in Neonatal Gram-negative Sepsis at a Tertiary Referral Unit in Harare, Zimbabwe.

Gwendoline Chimhini1, Ioana Diana Olaru1,2, Felicity Fitzgerald3, Mutsawashe Chisenga2, Cecilia Ferreyra4, Nada Malou4, Jeremie Piton4, Simbarashe Chimhuya1, Shunmay Yeung1,5, Surjo De6, Hilda A Mujuru1, Katharina Kranzer7,2,8.   

Abstract

BACKGROUND: Neonatal sepsis accounts for a large proportion of neonatal deaths in sub-Saharan Africa. The lack of access to diagnostic testing and excessively long turnaround times to result contributes to delays in sepsis identification and initiation of appropriate treatment. This study aims to evaluate the novel InTrays COLOREX Screen and extended-spectrum beta-lactamase for rapid identification of bacterial pathogens causing sepsis and detection of resistance.
METHODS: Neonates with suspected sepsis admitted to the Harare Central Hospital were prospectively enrolled. One blood culture was collected and incubated using the BacT/ALERT automated system. Positive blood cultures with potential pathogens identified by Gram stain were inoculated on the InTray COLOREX Screen and extended-spectrum beta-lactamase culture plates.
RESULTS: A total of 216 neonates with suspected sepsis were recruited. Pathogens were isolated from blood cultures in 56 (25.9%) neonates of which 54 were Klebsiella pneumoniae. All K. pneumoniae were resistant to ceftriaxone and 53 (98%) were resistant to gentamicin. Sensitivity and specificity for ceftriaxone-resistant K. pneumoniae detection using InTrays were 100%. InTrays results were interpretable as early as 5-10 hours (median 7 hours, interquartile range 7-7) post blood culture positivity enabling rapid identification and notification of result and leading to a 60% reduction in time to result from blood culture collection.
CONCLUSIONS: This study shows that the implementation of a novel culture method was feasible and reduced turnaround times for results by 60% compared with standard microbiologic techniques. An impact on patient outcomes and cost-effectiveness of this method needs to be demonstrated.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33941744      PMCID: PMC8677569          DOI: 10.1097/INF.0000000000003155

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   3.806


  18 in total

Review 1.  Diagnostics for neonatal sepsis: current approaches and future directions.

Authors:  Pui-Ying Iroh Tam; Catherine M Bendel
Journal:  Pediatr Res       Date:  2017-06-28       Impact factor: 3.756

Review 2.  Improving pathology and laboratory medicine in low-income and middle-income countries: roadmap to solutions.

Authors:  Shahin Sayed; William Cherniak; Mark Lawler; Soo Yong Tan; Wafaa El Sadr; Nicholas Wolf; Shannon Silkensen; Nathan Brand; Lai Meng Looi; Sanjay A Pai; Michael L Wilson; Danny Milner; John Flanigan; Kenneth A Fleming
Journal:  Lancet       Date:  2018-03-15       Impact factor: 79.321

3.  Rapid detection of bacteria in bloodstream infections using a molecular method: a pilot study with a neonatal diagnostic kit.

Authors:  Iolanda Mazzucchelli; Francesca Garofoli; Micol Angelini; Carmine Tinelli; Chryssoula Tzialla; Lidia Decembrino
Journal:  Mol Biol Rep       Date:  2019-10-22       Impact factor: 2.316

4.  Extended spectrum Beta-Lactamase-producing Klebsiella pneumoniae septicaemia outbreak in the Neonatal Intensive Care Unit of a tertiary hospital in Nigeria.

Authors:  K C Iregbu; U Anwaal
Journal:  Afr J Med Med Sci       Date:  2007-09

5.  Aetiology of invasive bacterial infection and antimicrobial resistance in neonates in sub-Saharan Africa: a systematic review and meta-analysis in line with the STROBE-NI reporting guidelines.

Authors:  Uduak Okomo; Edem N K Akpalu; Kirsty Le Doare; Anna Roca; Simon Cousens; Alexander Jarde; Mike Sharland; Beate Kampmann; Joy E Lawn
Journal:  Lancet Infect Dis       Date:  2019-09-12       Impact factor: 25.071

6.  Economic burden of neonatal sepsis in sub-Saharan Africa.

Authors:  Sylvia L Ranjeva; Benjamin C Warf; Steven J Schiff
Journal:  BMJ Glob Health       Date:  2018-01-12

7.  The interface between clinicians and laboratory staff: A field study in northern Tanzania.

Authors:  Coosje J Tuijn; Elizabeth Msoka; Declare L Mushi; Marion Sumari-de Boer; Jaffu Chilongola; Ankie van den Broek
Journal:  Afr J Lab Med       Date:  2014-07-23

Review 8.  Best Practices of Blood Cultures in Low- and Middle-Income Countries.

Authors:  Sien Ombelet; Barbara Barbé; Dissou Affolabi; Jean-Baptiste Ronat; Palpouguini Lompo; Octavie Lunguya; Jan Jacobs; Liselotte Hardy
Journal:  Front Med (Lausanne)       Date:  2019-06-18

9.  EUCAST rapid antimicrobial susceptibility testing (RAST) in blood cultures: validation in 55 European laboratories.

Authors:  Anna Åkerlund; Emma Jonasson; Erika Matuschek; Lena Serrander; Martin Sundqvist; Gunnar Kahlmeter
Journal:  J Antimicrob Chemother       Date:  2020-11-01       Impact factor: 5.790

10.  Auditing use of antibiotics in Zimbabwean neonates.

Authors:  G Chimhini; S Chimhuya; L Madzudzo; M Heys; C Crehan; V Robertson; R A Ferrand; B Sado; M Sharland; A S Walker; N Klein; F C Fitzgerald
Journal:  Infect Prev Pract       Date:  2020-02-19
View more
  2 in total

1.  Utility of InTray COLOREX Screen agar and InTray COLOREX ESBL agar for urine culture in the Lao PDR.

Authors:  Tamalee Roberts; Joy Silisouk; Davanh Sengdatka; Bountoy Sibounheuang; Ranoy Seljuk; Xao Vang; Amphonesavanh Sengduangphachanh; Viengmon Davong; Manivanh Vongsouvath; Nada Malou; Cecilia Ferreyra; Elizabeth A Ashley; Andrew J H Simpson
Journal:  JAC Antimicrob Resist       Date:  2022-02-07

2.  Effect of Risk-Focused Diversified Safety Management Mode in Patients with Major Artery Stent Implantation.

Authors:  Yan Shao; Cai-Juan Wu; Youjun Mao; Dong-Mei Li; Yun-Zhou Wang; Kang Zhu
Journal:  Emerg Med Int       Date:  2022-09-30       Impact factor: 1.621

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.